Latest From Ikaria Inc.
Medtech M&A activity has been on the rise for several years along with a surge in the number of higher-valued mega-deals, those worth at least $1 billion. Yet a survey of all deals with known values indicates that median deal value has actually declined.
Zogenix sold the Zohydro franchise to Pernix; AbbVie got its hands on Imbruvica through the $20 billion takeover of Pharmacyclics. Biopharma financing reached a six-month high in March, while in medtech the total was a six-month low.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.
- Monitoring Equipment & Devices
- Drug Delivery
- Therapeutic Areas
- Renal System
- Respiratory, Pulmonary
- INO Therapeutics LLC
- North America
- Parent & Subsidiaries
- Ikaria Inc.
- Senior Management
Daniel Tasse, Chmn. & CEO
Tasos G Konidaris, EVP, CFO & Corp. Dev.
Douglas Greene, MD, EVP, CSO
Stephen Ross, EVP, Chief Commerical Officer
- Contact Info
Phone: (908) 238-6600
Perryville III Corp. Pk. 53 Frontage Rd.
P.O. Box 9001 Hampton, NJ 08827-9001
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.